Profile of Inflammation-Associated Proteins in Early Post-Transplant Samples of Patients After Allogeneic Hematopoietic Stem Cell Transplantation: a Preliminary Study

  • Frantisek Mrazek
  • Petra Schneiderova
  • Eva Kriegova
  • Ludek Raida
  • Adam Kuba
  • Petr Gajdos
  • Nikola Königova
  • Jana Onderkova
  • Zuzana Ambruzova
Original Article


Allogeneic hematopoietic stem cell transplantation (aHSCT) is used as a curative treatment in severe hematological and immunological disorders. Despite clear improvement of the aHSCT outcome, substantial proportion of patients still suffers from severe complications, including graft-versus-host disease (GvHD). The aim of this study was, therefore, to identify inflammation-associated molecules deregulated in the early serum samples of the patients after aHSCT and nominate markers associated with particular aHSCT parameters/complications. Serum concentrations of 92 inflammation-associated proteins were measured in samples obtained from 80 aHSCT patients 14 days after transplantation and from 23 healthy control subjects by a novel sensitive proximity extension assay technology using Proseek Multiplex Inflammation I kit. Serum profiles of inflammatory proteins in patients after aHSCT were substantially different from those observed in control subjects and related to underlying disease status before transplantation. Particularly, the difference between aHSCT patients and controls reached significance level for 57 analytes (40 upregulated, 17 downregulated in aHSCT patients). The concentration of several markers was associated with the level of donor/recipient HLA match (TGF-α: p corr = 0.025, HGF: p corr = 0.036) and with complete donor chimerism at day +30 after allografting (DNER: p corr = 0.042). None of the markers was significantly associated with acute and chronic GvHD after correction. More than half of investigated proteins significantly differed between the samples from aHSCT patients and healthy control subjects as a consequence of the “cytokine storm” after aHSCT. Comparisons of patient’s subgroups based on specific biological/clinical parameters revealed much less evident differences; nevertheless, we nominated several markers associated with the level of donor/recipient HLA match and post-transplant chimerism.


Hematopoetic stem cell transplantation Graft-versus-host disease Protein profiles Biomarkers Inflammation 



Supported by the Ministry of Health of the Czech Republic projects IGA MH CZ NT12454-5 and MH CZ-DRO (FNOl, 00098892), and by Palacky University Olomouc project IGA_LF_2016_011.

Supplementary material

5_2016_446_MOESM1_ESM.doc (166 kb)
Supplementary material 1 (DOC 165 kb)


  1. Ambruzova Z, Mrazek F, Raida L et al (2009) Possible impact of MAdCAM1 gene single nucleotide polymorphisms to the outcome of allogeneic haematopoietic stem cell transplantation. Hum Immunol 70:457–460CrossRefPubMedGoogle Scholar
  2. Assarsson E, Lundberg M, Holmquist G et al (2014) Homogenous 96-plex PEA immunoassay exhibiting high sensitivity, specificity, and excellent scalability. PLoS One 9:e95192CrossRefPubMedPubMedCentralGoogle Scholar
  3. Benjamini Y, Hochberg Y (1995) Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Ser B57:289–300Google Scholar
  4. Cahn JY, Klein JP, Lee SJ et al (2005) Prospective evaluation of 2 acute graft-versus-host (GVHD) grading systems: a joint Société Française de Greffe de Moëlle et Thérapie Cellulaire (SFGM-TC), Dana Farber Cancer Institute (DFCI), and International Bone Marrow Transplant Registry (IBMTR) prospective study. Blood 106:1495–1500CrossRefPubMedPubMedCentralGoogle Scholar
  5. Chien JW, Zhang XC, Fan W et al (2012) Evaluation of published single nucleotide polymorphisms associated with acute GVHD. Blood 119:5311–5319CrossRefPubMedPubMedCentralGoogle Scholar
  6. Choi SW, Reddy P (2014) Current and emerging strategies for the prevention of graft-versus-host disease. Nat Rev Clin Oncol 11:536–547CrossRefPubMedPubMedCentralGoogle Scholar
  7. Cooley S, Weisdorf DJ, Guethlein LA et al (2010) Donor selection for natural killer cell receptor genes leads to superior survival after unrelated transplantation for acute myelogenous leukemia. Blood 116:2411–2419CrossRefPubMedPubMedCentralGoogle Scholar
  8. Ferrara JL, Levine JE, Reddy P et al (2009) Graft-versus-host disease. Lancet 373:1550–1561CrossRefPubMedPubMedCentralGoogle Scholar
  9. Fiema B, Harris AC, Gomez A et al (2012) High throughput sequential ELISA for validation of biomarkers of acute graft-versus-host disease. J Vis Exp 68:pii 4247Google Scholar
  10. Frampton JP, White JB, Simon AB et al (2014) Aqueous two-phase system patterning of detection antibody solutions for cross-reaction-free multiplex ELISA. Sci Rep 4:4878CrossRefPubMedPubMedCentralGoogle Scholar
  11. Gao L, Yuan K, Ding W et al (2016) Notch signaling: a potential therapeutic target for hematologic malignancies. Crit Rev Eukaryot Gene Expr 26:239–246CrossRefPubMedGoogle Scholar
  12. Gratwohl A, Baldomero H, Passweg J (2013) Hematopoietic stem cell transplantation activity in Europe. Curr Opin Hematol 20:485–493CrossRefPubMedGoogle Scholar
  13. Greene M, Lai Y, Pajcini K et al (2016) Delta/Notch-like EGF-related receptor (DNER) is not a Notch ligand. PLoS One 11:e0161157CrossRefPubMedPubMedCentralGoogle Scholar
  14. Hill GR, Crawford JM, Cooke KR et al (1997) Total body irradiation and acute graft-versus-host disease: the role of gastrointestinal damage and inflammatory cytokines. Blood 90:3204–3213PubMedGoogle Scholar
  15. Holtan SG, Verneris MR, Schultz KR et al (2015) Circulating angiogenic factors associated with response and survival in patients with acute graft-versus-host disease: results from Blood and Marrow Transplant Clinical Trials Network 0302 and 0802. Biol Blood Marrow Transplant 21:1029–1036CrossRefPubMedPubMedCentralGoogle Scholar
  16. Hori T, Naishiro Y, Sohma H et al (2008) CCL8 is a potential molecular candidate for the diagnosis of graft-versus-host disease. Blood 111:4403–4412CrossRefPubMedPubMedCentralGoogle Scholar
  17. Levine JE, Braun TM, Harris AC et al (2015) A prognostic score for acute graft-versus-host disease based on biomarkers: a multicenter study. Lancet Haematol 2:e21–e29CrossRefPubMedPubMedCentralGoogle Scholar
  18. Lundberg M, Eriksson A, Tran B et al (2011) Homogeneous antibody-based proximity extension assays provide sensitive and specific detection of low-abundant proteins in human blood. Nucleic Acids Res 39:e102CrossRefPubMedPubMedCentralGoogle Scholar
  19. MacMillan ML, Davies SM, Nelson GO et al (2008) Twenty years of unrelated donor bone marrow transplantation for pediatric acute leukemia facilitated by the National Marrow Donor Program. Biol Blood Marrow Transplant 14(9 Suppl):16–22CrossRefPubMedGoogle Scholar
  20. Magenau JM, Qin X, Tawara I et al (2010) Frequency of CD4(+)CD25(hi)FOXP3(+) regulatory T cells has diagnostic and prognostic value as a biomarker for acute graft-versus-host-disease. Biol Blood Marrow Transplant 16:907–914CrossRefPubMedPubMedCentralGoogle Scholar
  21. Paczesny S, Krijanovski OI, Braun TM et al (2009) A biomarker panel for acute graft-versus-host disease. Blood 113:273–278CrossRefPubMedPubMedCentralGoogle Scholar
  22. Paczesny S, Braun TM, Levine JE et al (2010) Elafin is a biomarker of graft-versus-host disease of the skin. Sci Transl Med 2:13ra2CrossRefPubMedPubMedCentralGoogle Scholar
  23. Paczesny S, Raiker N, Brooks S et al (2013) Graft-versus-host disease biomarkers: omics and personalized medicine. Int J Hematol 98:275–292CrossRefPubMedPubMedCentralGoogle Scholar
  24. Petersdorf EW (2008) Optimal HLA matching in hematopoietic cell transplantation. Curr Opin Immunol 20:588–593CrossRefPubMedPubMedCentralGoogle Scholar
  25. Politikos I, Kim HT, Nikiforow S et al (2015) IL-7 and SCF levels inversely correlate with T cell reconstitution and clinical outcomes after cord blood transplantation in adults. PLoS One 10:e0132564CrossRefPubMedPubMedCentralGoogle Scholar
  26. Przepiorka D, Weisdorf D, Martin P et al (1995) 1994 consensus conference on acute GVHD grading. Bone Marrow Transplant 15:825–828 PubMedGoogle Scholar
  27. Reikvam H, Mosevoll KA, Melve GK et al (2012) The pretransplantation serum cytokine profile in allogeneic stem cell recipients differs from healthy individuals, and various profiles are associated with different risks of posttransplantation complications. Biol Blood Marrow Transplant 18:190–199CrossRefPubMedGoogle Scholar
  28. Shaw BE, Lee F, Krishnamurthy S et al (2015) Caspase-8 polymorphisms result in reduced Alemtuzumab-induced T-cell apoptosis and worse survival after transplantation. Bone Marrow Transplant 50:237–243CrossRefPubMedGoogle Scholar
  29. Sullivan KM, Agura E, Anasetti C et al (1991) Chronic graft-versus-host disease and other late complications of bone marrow transplantation. Semin Hematol 28:250–259PubMedGoogle Scholar
  30. Toubai T, Tanaka J, Paczesny S et al (2012) Role of cytokines in the pathophysiology of acute graft-versus-host disease (GVHD): are serum/plasma cytokines potential biomarkers for diagnosis of acute GVHD following allogeneic hematopoietic cell transplantation (allo-HCT)? Curr Stem Cell Res Ther 7:229–239CrossRefPubMedGoogle Scholar
  31. Xun CQ, Thompson JS, Jennings CD et al (1994) Effect of total body irradiation, busulfan-cyclophosphamide, or cyclophosphamide conditioning on inflammatory cytokine release and development of acute and chronic graft-versus-host disease in H-2-incompatible transplanted SCID mice. Blood 83:2360–2367PubMedGoogle Scholar

Copyright information

© L. Hirszfeld Institute of Immunology and Experimental Therapy, Wroclaw, Poland 2016

Authors and Affiliations

  1. 1.Department of Immunology, Faculty of Medicine and DentistryPalacky University and University HospitalOlomoucCzech Republic
  2. 2.Department of Haemato-Oncology, Faculty of Medicine and DentistryPalacky University and University HospitalOlomoucCzech Republic
  3. 3.Department of Computer Science, Faculty of Electrical Engineering and Computer ScienceVSB-Technical University of OstravaOstravaCzech Republic

Personalised recommendations